Affiliation:
1. Laboratory of Cell and Gene Therapy, Centre for Basic Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 115 27 Athens, Greece
2. Laboratory of Biology, University of Athens School of Medicine, 115 27 Athens, Greece
Abstract
β-thalassemia is characterized by reduced or absence ofβ-globin production, resulting in anemia. Current therapies include blood transfusion combined with iron chelation. BM transplantation, although curative, is restricted by the matched donor limitation. Gene therapy, on the other hand, is promising, and its success lies primarily on designing efficient globin vectors that can effectively and stably transduce HSCs. The major breakthrough inβ-thalassemia gene therapy occurred a decade ago with the development of globin LVs. Since then, researchers focused on designing efficient and safe vectors, which can successfully deliver the therapeutic transgene, demonstrating no insertional mutagenesis. Furthermore, as human HSCs have intrinsic barriers to HIV-1 infection, attention is drawn towards theirex vivomanipulation, aiming to achieve higher yield of genetically modified HSCs. This paper presents the current status of gene therapy forβ-thalassemia, its success and limitations, and the novel promising strategies available involving the therapeutic role of HSCs.
Subject
Cell Biology,Molecular Biology
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献